| Pharmaceutical Information |
| Drug Name |
Profenamine |
| Drug ID |
BADD_D02632 |
| Description |
Profenamine is a medication derived from phenothiazine. It is primarily used as an antidyskinetic to treat parkinsonism. It is sold under the trade names Parsidol in the United States and Parsidan in Canada. |
| Indications and Usage |
For use in the treatment of Parkinson's disease and also used to control severe reactions to certain medicines such as reserpine. |
| Marketing Status |
approved |
| ATC Code |
N04AA05 |
| DrugBank ID |
DB00392
|
| KEGG ID |
D08426
|
| MeSH ID |
C084820
|
| PubChem ID |
3290
|
| TTD Drug ID |
D0Q0RC
|
| NDC Product Code |
Not Available |
| UNII |
7WI4P02YN1
|
| Synonyms |
profenamine | ethopropazine | Parsidol | Parsitan | Lysivane | profenamine hydrochloride | ethopropazine hydrochloride |
|
| Chemical Information |
| Molecular Formula |
C19H24N2S |
| CAS Registry Number |
522-00-9 |
| SMILES |
CCN(CC)C(C)CN1C2=CC=CC=C2SC3=CC=CC=C31 |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
| ADR Term |
ADReCS ID |
ADR Frequency (FAERS)
|
ADR Severity Grade (FAERS)
|
ADR Severity Grade (CTCAE)
|
| Akinesia | 17.01.02.003 | - | - | Not Available | | Dry mouth | 07.06.01.002 | - | - | | | Headache | 17.14.01.001 | - | - | | | Hypertonia | 17.05.02.001; 15.05.04.007 | - | - | Not Available | | Oculogyric crisis | 17.01.03.002; 06.05.02.002 | - | - | Not Available | | Somnolence | 17.02.04.006; 19.02.05.003 | - | - | | | Tremor | 17.01.06.002 | - | - | |
|
The 1th Page
1
Total 1 Pages
|
|
